{'fraction_non_alphanumeric': 0.020604395604395604, 'fraction_numerical': 0.0, 'mean_word_length': 5.813084112149533, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibition of type I allergic responses with nanogram doses of replicon‐based DNA vaccines

Background:  Allergic diseases have become a major public health problem in developed countries; yet, no reliable, safe and consistently effective treatment is available. DNA immunization has been shown to prevent and balance established allergic responses, however, the high dose of conventional DNA vaccines necessary for the induction of anti‐allergic reactions and their poor immunogenicity in primates require the development of new allergy DNA vaccines. We evaluated protective and therapeutic effects of a Semliki‐Forest Virus replicase‐based vs a conventional DNA vaccine in BALB/c mice using the model allergen β‐galactosidase.